• Pelthos Therapeutics’ third-quarter 2026 net loss narrowed 51% year over year to $7.9 million.
• Zelsuvmi net product revenue more than doubled year over year to $15.2 million.
• Selling, general and administrative expenses fell 25% from the second quarter of 2026 to $18.8 million.
• The planned Castle Creek merger remains on track to close by the end of the first quarter of 2027, subject to conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pelthos Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001919246-26-000134), on November 12, 2026, and is solely responsible for the information contained therein.